Synopsis
Selling weight-loss drugs is an opportunity no pharma company wants to miss. Now a leading drug maker from India joins this bandwagon.
Trust Sun Pharma boss Dilip Shanghvi to be at the cutting-edge of research. After building a band of specialty drugs that exceeds a billion dollars in sales globally, Shanghvi has placed his bets on weight-loss or anti-obesity drugs, a field that has sent pharmaceutical companies across the world in a hot pursuit. Riding on blockbusters such as Ozempic, Wegovy, and Zepbound, their makers Novo Nordisk and Eli Lilly are ranked the most valuable
- FONT SIZE
AbcSmall
AbcMedium
AbcLarge
Refer & Earn
Uh-oh! This is an exclusive story available for selected readers only.
Worry not. You’re just a step away.